Chronic Spontaneous Urticaria in Adult Patients: Evaluating the Effect of Loratadine on Weight and Metabolic Syndrome

Antihistamine is standard chronic spontaneous urticaria (CSU) therapy. Weight gain a side effect of concern as prolonged high dose therapy common. We investigated the effects 12-weeks loratadine on weight, appetite and parameters metabolic syndrome (MetS). A cohort study was performed involving CSU patients aged ≥18 years. Patients with diseases or drugs affecting weight were excluded. treated according to management. Weight, height, waist circumference (WC), body mass index (BMI) blood pressure (BP), Urticaria Activity Score 7 (UAS7), Dermatology Life Quality Index (DLQI), hunger satiety questionnaire, fasting sugar (FBS) lipid profile (FLP) obtained at baseline, week 6 12. Loratadine cumulative determined. Thirteen (33.33 %) males 26 (66.67 females 33.00 (12.00) years participated. Median 62.55 (18.30) kg, BMI 24.60 (6.80) kg/m2, 13(33.33%) had normal 12 (30.77%) overweight, 11 (28.21%) obese 3 (7.69%) underweight. Significant observed 6, 67.56 ± 16.14 kg vs 68.16 16.95 p < 0.05 64.73 14.60 = 0.04 Changes in BMI, WC, BP, FBS FLP insignificant. Three developed MetS. Hunger scores unaffected. induced despite no appetite. should be monitored long term Keywords: Urticaria; loratadine; gain; syndrome;